AMG 333
ApprovedSmall molecule
AmgenAMG 333 is one of 1337 small molecule programs targeting Glioma. It is currently in Approved.
54
Indications
182
Total Trials
16
Active Trials
1,336
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 54 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1AMG 333
AmgenApproved
Tecentriq
RochePreclinical
Halaven
EisaiPreclinical
DATROWAY
Daiichi SankyoPreclinical
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors9 trials
Show 6 more trials
Tics8 trials
Show 5 more trials
Non-Small Cell Lung Cancer6 trials
Systemic Lupus Erythematosus6 trials
Show 3 more trials
Asthma5 trials
95 more indications
Breast Cancer5 trials
Migraine4 trials
Schizophrenia4 trials
Rheumatoid Arthritis4 trials
Multiple Myeloma4 trials
Interaction4 trials
Show 1 more trial
ESS3 trials
Solid Tumors3 trials
Patients With Advanced Solid Tumors3 trials
Acute Myeloid Leukemia3 trials
Obesity3 trials
Secondary Hyperparathyroidism3 trials
Efficacy3 trials
ART3 trials
Psoriasis2 trials
Overweight2 trials
Impaired Renal Function2 trials
Ovarian Cancer2 trials
Prostate Cancer2 trials
Type 2 Diabetes Mellitus2 trials
Pancreatic Cancer2 trials
Gastrointestinal Stromal Tumor2 trials
Celiac Disease2 trials
Advanced NSCLC2 trials
Low Bone Mineral Density2 trials
Type 2 Diabetes2 trials
Small Cell Lung Cancer2 trials
Safety and Efficacy2 trials
Thyroid Eye Disease2 trials
Non-Alcoholic Fatty Liver Disease1 trial
Thoracic Tumors1 trial
Absorption1 trial
Postmenopausal Women1 trial
Cutaneous Lupus Erythematosus1 trial
Thyroid Cancer1 trial
Hepatocellular Cancer1 trial
Metastatic Prostate Cancer1 trial
Bevacizumab1 trial
Relapsed or Refractory1 trial
Drug Interactions1 trial
Immunogenicity1 trial
Ulcerative Colitis1 trial
Hematological Malignancies1 trial
Chronic Myelomonocytic Leukemia1 trial
Hematologic Malignancies1 trial
Osteoarthritis1 trial
Anemia1 trial
Vitiligo1 trial
Evaluation of AMG 714 for Vitiligo
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04338581·60 enrolled
Relapsed/Refractory AML1 trial
Urothelial Carcinoma1 trial
Advanced MTAP-null Solid Tumors1 trial
Esophageal Adenocarcinoma1 trial
Phase 11 trial
Neuroendocrine Tumors1 trial
Colorectal Carcinoma1 trial
Intestinal Cancer1 trial
Metastasis1 trial
Postmenopausal Osteoporosis1 trial
Chronic Kidney Disease1 trial
Metastatic Colorectal Cancer1 trial
Heart Failure1 trial
Osteoporosis1 trial
Double-blind1 trial
Impairment1 trial
Atopic Asthma1 trial
Gastroesophageal Junction Adenocarcinoma1 trial
Primary Hyperparathyroidism1 trial
Prostate Carcinoma1 trial
Hepatic Impairment1 trial
Recurrent Epithelial Ovarian1 trial
Advanced Cancer1 trial
Fallopian Tube Cancer1 trial
Lung Cancer1 trial
Cardiometabolic Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMG 333. EMBL-EBI & Wellcome Sanger Institute.
- [4]